Granted Patent
B2
US 12,673,050 · App. 18/540,695 · Granted Jul 7, 2026
Compositions and their use for the treatment of A1-antitrypsin deficiency
Inventors:
Nigel Ramsden (Babraham, GB); David John Fox (Babraham, GB); James Andrew Huntington (Altrincham, GB)
Assignee:
CENTESSA PHARMACEUTICALS (UK) LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to pharmaceutical compositions comprising (S)-1-(2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid and their medical use, for example for use in the treatment of α 1 -antitrypsin deficiency (AATD).
Claims (11)
1 . A method of treating a disease or disorder characterised by low plasma levels of A1AT in a human subject, comprising the step of administering a pharmaceutical composition comprising(S)-1-((2-(trifluoromethyl)phenyl)sulfonyl)piperidine-3-carboxylic acid
or a pharmaceutically acceptable salt form,
and a pharmaceutically or therapeutically acceptable excipient or carrier, at a daily dose of about 1-6 mg/kg.
2 . The method of claim 1 , in which the disease or disorder is a1-antitrypsin deficiency (AATD).
3 . The method of claim 1 , wherein the administering to the human subject is at a daily dose of about 2-5 mg/kg.
4 . The method of claim 3 , wherein the daily dose is about 2 mg/kg.
5 . The method of claim 3 , wherein the daily dose is about 3 mg/kg.
6 . The method of claim 3 , wherein the daily dose is about 4 mg/kg.
7 . The method of claim 3 , wherein the daily dose is about 5 mg/kg.
8 . The method of claim 1 , wherein the composition is administered in oral form.
9 . The method of claim 1 , wherein the composition is administered intravenously.
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST
Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 23, 2024
From: RAMSDEN, NIGEL; FOX, DAVID JOHN; HUNTINGTON, JAMES ANDREW
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 066542/0479 →
Priority Claims (1)
GB 2108523
· Jun 15, 2021
· national
Continuity (2)
Continuation
PCTGB2022051502
· Jun 15, 2022
References Cited (52)
US 8436013B2
· Liu et al.
· 2013
[cited by applicant]
US 9084782B2
· Kwon et al.
· 2015
[cited by applicant]
US 20110065707A1
· Ackermann et al.
· 2011
[cited by applicant]
EP 0520336A2
· 1992
[cited by applicant]
JP H05345753A
· 1993
[cited by applicant]
JP 2007538106A
· 2007
[cited by applicant]
JP 2013504544A
· 2013
[cited by applicant]
WO WO2005113542A2
· 2005
[cited by applicant]
WO WO2008143633A2
· 2008
[cited by applicant]
WO WO2011029808A1
· 2011
[cited by applicant]
WO WO2011110852A1
· 2011
[cited by applicant]
WO WO2018104220A1
· 2018
[cited by applicant]
WO WO2019243841A1
· 2019
[cited by applicant]
WO WO2020081257A1
· 2020
[cited by applicant]
WO WO2021116703A1
· 2021
[cited by applicant]
WO WO2022263816A1
· 2022
[cited by applicant]
Chemical Abstracts Service. CAS Registry: 1786870-80-1. STN Entry Date Jun. 23, 2015.
[cited by applicant]
Chemical Abstracts Service. CAS Registry: 2649795-64-0. STN Entry Date Jul. 6, 2021.
[cited by applicant]
Chemical Abstracts Service. CAS Registry: 727983-32-6. STN Entry Date Aug. 18, 2004.
[cited by applicant]
Chemical Abstracts Service. CAS Registry: 891392-15-7. STN Entry Date Jul. 10, 2006.
[cited by applicant]
Berthelier et al., “Discovery Of An Inhibitor Of Z-Alpha1 Antitrypsin Polymerization,” PLoS One 10(5)(e0126256):1-18 (May 11, 2015).
[cited by applicant]
Bouchecareilh et al., Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. The Journal of biological chemistry 287(45):38265-38278 (2012).
[cited by applicant]
Burrows et al., “Chemical Chaperones Mediate Increased Secretion Of Mutant α1-Antitrypsin (α1-AT) Z: A Potential Pharmacological Strategy For Prevention Of Liver Injury And Emphysema In α1-AT Deficiency,” Proceedings of…
[cited by applicant]
Carlson et al., “Accumulation of PiZ Alpha 1-Antitrypsin Causes Liver Damage In Transgenic Mice,” The Journal of Clinical Investigation 83(4):1183-1190 (1989).
[cited by applicant]
Certified GB1918410.0, filed Dec. 13, 2019.
[cited by applicant]
Chang et al., “Small-Molecule Peptides Inhibit Z α1-Antitrypsin Polymerization,” Journal of Cellular and Molecular Medicine 13(8B):2304-2316 (2009).
[cited by applicant]
Corral et al., “Exploiting The Evolutionary Relationship Between Malarial Parasites And Plants To Develop New Herbicides,” Angewandte Chemie International Edition English 56(33):9881-9885 (Jul. 12, 2017).
[cited by applicant]
Database accession No. 1394768-24-1, Chemical Abstracts Service (Sep. 18, 2012).
[cited by applicant]
Database Accession No. 1786658-64-7, Registry, Chemical Abstracts Service, Columbus, Ohio, US, 01 Page (Jun. 23, 2015), XP002801653.
[cited by applicant]
Database Accession No. 1786746-43-7, Registry, Chemical Abstracts Service, Columbus, Ohio, US, 01 Page (Jun. 23, 2015), XP002801660.
[cited by applicant]
Database accession No. 1840546-43-1, Chemical Abstracts Service (Jan. 3, 2016).
[cited by applicant]
Database accession No. 727717-69-3, Chemical Abstracts Service (Aug. 17, 2004).
[cited by applicant]
Database accession No. 891392-68-0, Chemical Abstracts Service (Jul. 10, 2006).
[cited by applicant]
Dycaico et al., “Neonatal Hepatitis Induced by Alpha 1-Antitrypsin: A Transgenic Mouse Model,” Science 242(4884):1409-1412 (Dec. 9, 1988).
[cited by applicant]
Elkins et al., “Variability in High-throughput Ion-Channel Screening Data and Consequences for Cardiac Safety Assessment,” Journal of Pharmacological and Toxicological Methods 68:112-122 (2013).
[cited by applicant]
Elliott et al., “Topography of a 2.0 A Structure of Alpha1-Antitrypsin Reveals Targets for Rational Drug Design to Prevent Conformational Disease,” Protein Science 9:1274-1281 (2000).
[cited by applicant]
GB1918410.0 Search Report dated Jun. 10, 2020.
[cited by applicant]
Gould. Salt Selection for Basic Drugs. International Journal of Pharmaceutics, Elsevier, Biomedical Division, NL 33(1-3):201-217 (1986) Retrieved on Nov. 1, 1986].
[cited by applicant]
Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services-FDA, Jul. 2005, Retrieved from the I…
[cited by applicant]
Huntington “How And Why The Z Variant Of α1-Antitrypsin Polymerises, And What Can Be Done About It,” 7th International Symposium On Serpin Biology, Structure And Function, Powerpoint Presentation, 34 Pages (Apr. 1, 2014…
[cited by applicant]
Knaupp et al., “Kinetic Instability of the Serpin Z Alpha1-Antitrypsin Promotes Aggregation,” Journal of Molecular Biology 396:375-383 (2010) (Available Online on Nov. 26, 2009).
[cited by applicant]
Mallya, Meera, et al., Small Molecules Block The Polymerization Of Z Alpha1-antitrypsin And Increase The Clearance Of Intracellular Aggregates. Journal of Medicinal Chemistry 50(22):5357-5363 (2007).
[cited by applicant]
Parfrey et al., “Targeting a Surface Cavity of Alpha 1-Antitrypsin to Prevent Conformational Disease,” The Journal of Biological Chemistry 278(35):33060-33066 (Aug. 29, 2003).
[cited by applicant]
PCT/GB2020/053187 International Search Report and Written Opinion dated Feb. 1, 2021.
[cited by applicant]
PCT/GB2022/051502 International Search Report and Written Opinion dated Aug. 17, 2022.
[cited by applicant]
Reddy et al., “Synthesis And Antimicrobial Screening Of Some New Piperidine Derivatives,” Journal of Applicable Chemistry 2(6):1501-1508 (2013).
[cited by applicant]
Registry, Chemical Abstracts Service, Columbus, Ohio, US, Database accession No. 1787438-88-3 (Jun. 24, 2015), XP002801654.
[cited by applicant]
Registry, Chemical Abstracts Service, Columbus, Ohio, US, Database accession No. 630049-57-9, (Dec. 23, 2003), XP002801655.
[cited by applicant]
Seyama et al., “Siiyama (Serine 53 (TCC) to Phenylalanine 53 (TTC)). A New Alpha 1-Antitrypsin-Deficient Variant with Mutation on a Predicted Conserved Residue of the Serpin Backbone,” The Journal of Biological Chemistr…
[cited by applicant]
Weaver et al., “Cytochrome P450 Inhibition Using Recombinant Proteins And Mass Spectrometry/multiple Reaction Monitoring Technology In A Cassette Incubation,” Drug Metabolism and Disposition 31(7):955-966 (2003).
[cited by applicant]